28.06.2023
Since its foundation in 2018, Austria-based Biome Diagnostics has been developing innovative microbiome-based technologies that use machine learning and DNA sequencing to analyze microbial functions. The company sees itself as an interface between cutting-edge DNA technology and precise AI applications - the aim is to develop first-class microbiome diagnostics and therapies that can be used in routine care and thus revolutionize cancer prevention in the future.
Partnership for the future
As an exploratory start-up of the UNIQA Group, innovative solutions are the top priority for SanusX. In addition to its own research work, SanusX regularly invests in up-and-coming medtech start-ups.
Together, SanusX and Biome Diagnostics now want to continue to grow and create new synergies in order to help even more people with new, accessible solutions in the healthcare sector.
Binder Grösswang as advisor to Biome Diagnostics
The Binder Grösswang team led by venture capital specialist Christian Zwick advised Biome Diagnostics on all legal aspects of the investment round. In particular with regard to investment law and regulatory issues.
"We are very proud to be able to support Biome Diagnostics, a long-standing client of the firm, in this important step," says Christian Zwick, partner at Binder Grösswang. "Biome Diagnostics is doing pioneering medical work that will continue to play a major role for all of us."
The Binder Grösswang team included Christian Zwick (Partner, Corporate/M&A), as well as Michael Mittermair (Associate, Corporate/M&A), Christine Dietz (Partner, EU & Competition), Christoph Raab (Senior Associate, EU Competition), Michael Horak (Partner, Intellectual Property & Information Technology) and Sabine Apfl-Trompeter (Senior Associate, Employment).